Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Competitor Analysis: Notch Pathway Inhibitors

Published by: La Merie Publishing

Published: Feb. 1, 2010 - 10 Pages


Table of Contents


Index
  • Notch Pathway Inhibitors

  • Corporate Notch Pathway Inhibitor R&D Pipelines

  • About La Merie



    • Abstract

    The present Competitive Intelligence Report about Notch Pathway Inhibitors provides a competitor evaluation in the field of molecules targeting Notch via gamma-secretase or its vascular ligand delta-like ligand-4 (DLL4) as of February 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

    The Notch signaling pathway has been found to play central roles in humans in stem cell maintenance, cell fate decisions, and in cancer as well. Notch family members are being revealed as oncogenes in an ever-increasing number of cancers. Notch signaling is also thought to be important for the maintenance of cancer stem cell populations in tumors. Cancer stem cells may cause tumor metastasis and relapse following anti-tumor treatments by regenerating the tumor tissue. Eradication of cancer stem cells may lead to increased survival in cancer patients.

    First generation Notch inhibitors have entered clinical testing. Use of gamma secretase inhibitors may be associated with gastro-intestinal on-target side effects such as diarrhea. Targeting the vascular ligand of Notch (delta-like ligand 4, DLL4) by antibodies may offer tremendous promise as novel anti-tumor agents. At present, five different constructs targeting Notch/DLL4 are in early clinical development.

    The report includes a compilation of currently active projects in research and development of small molecules, antibodies, proteins and vaccines targeting targeting the Notch pathway for treatment of cancer. In addition, the report lists company-specific R&D pipelines of Notch Pathway Inhibitors. Competitor projects are listed in a tabular format providing information on:
    • Drug Codes,
    • Target / Mechanism of Action,
    • Class of Compound,
    • Company,
    • Product Category,
    • Indication,
    • R&D Stage and
    • additional comments with a hyperlink leading to the source of information.


    Get Full Details About This Report >>
    US: 800.298.5699
    Int'l: +1.240.747.3093
    Buy this Report
    Price and Delivery Options
    Search Inside Report


     

    About MarketResearch.com
    MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

     

    © MarketResearch.com 2012
    2/15/2012 - 31